Risperdal Settlement
August 10, 2011, by Ronald V. Miller, Jr.
Johnson & Johnson will settle a misdemeanor criminal charge involving the marketing of its psychiatric drug Risperdal.
J&J said in a regulatory filing that the agreement related to an allegation that the company promoted Risperdal for unapproved uses. The agreement, which has not been finalized, was disclosed in a filing with the Securities and Exchange Commission.
The settlement amount was not disclosed. You can read more at CNBC here.
